Lipoarabinomannan

Lipoarabinomannan, also called LAM, is a glycolipid, and a virulence factor associated with Mycobacterium tuberculosis, the bacteria responsible for tuberculosis. Its primary function is to inactivate macrophages and scavenge oxidative radicals.

The inactivation of macrophages allows for the dissemination of mycobacteria to other parts of the body. The destruction of oxidative radicals allows for the survival of the bacteria, as oxidative free radicals are an important mechanism by which our bodies try to rid ourselves of infection.

Background

Lipoarabinomannan is a lipoglycan and major virulence factor in the bacteria genus Mycobacterium. In addition to serving as a major cell wall component, it is thought to serve as a modulin with immunoregulatory and anti-inflammatory effects. This allows the bacterium maintain survival in the human reservoir by undermining host resistance and acquired immune responses.[1] These mechanisms include the inhibition of T-cell proliferation and of macrophage microbicidal activity via diminished IFN-γ response. [2] Additional functions of lipoarabinommanan are thought to include the neutralization of cytotoxic oxygen free radicals produced by macrophages, inhibition of protein kinase C, and induction of early response genes.[3]

Structure

Lipoarabinomannan is synthesized via addition of mannose residues to phosphoinositol by a series of mannosyltransferases to produce PIMs and lipomannan(LM).[4][5][6] PIM and LM are then glycosylated with arabinan to form LAM.[7] LAM is known to have three primary structural domains. These include a glycosylphosphatidyl anchor which attaches the molecule to the cell wall, a D-mannan core serving as a carbohydrate skeleton, and a terminal D-arabinan, also composing the carbohydrate skeleton.[7] Many arabinofuranosyl side chains branch off the mannose core.[8] It is the covalent modifications to this terminal D-arabinan that creates various LAM structures with their own unique functions to mediate bacterial survival within a host. The presence and the structure of capping allow classification of LAM molecules into three major classes.

ManLAM

Mannosylated LAMs (ManLAM) are characterized by the presence of mannosyl caps on the terminal D-arabinan. These types of LAMs are most commonly found in more pathogenic Mycobacterium species such as M. tuberculosis, M. leprae, and M. bovis. ManLAM has been shown to be an anti-inflammatory molecule that inhibits production of TNF-α and IL-12 production by human dendritic cells and human macrophages in vitro and to modulate M. tuberculosis-induced macrophage apoptosis via binding to host macrophage mannose receptors.[1][9] This is particularly important in deactivating host macrophages to allow the bacteria to survive and multiply within them.[2]

Proposed Mechanisms

There are many proposed mechanisms behind ManLAM function. Activation of a PI3K pathway is sufficient to trigger phosphorylation of the Bcl-2 family member Bad by ManLAM. ManLAM is able to activate the serine/threonine kinase Akt via phosphorylation which is then able to phosphorylate Bad. Dephosphorylated Bad serves as a pro-apoptotic protein and its activation allows for cell survival. This demonstrates one virulence-associated mechanism by which bacteria are able to up-regulate signaling pathways to control host cell apoptosis.[8]

ManLAM may also directly activate SHP-1, a phosphotyrosine phosphatase known to be involved in terminating activation signals. SHP-1 negatively regulates pathways related to the actions of IFN-γ and insulin. LAM may regulate SHP-1 by multiple mechanisms including direct interactions, phosphorylation, and subcellular localization. Once activated, SHP-1 translocates from the cytosol to the membrane. By activating a phosphatase, LAM can inhibit LPS and IFN-γ induced protein tyrosine phosphorylation in monocytes. This decreases production of TNF-α, a molecule necessary in forming granulomas against M. tuberculosis and important in macrophage defense against bacterium via nitrogen oxide production. LAM's activation of SHP-1 also works to deactivate IL-12. IL-12 is important for innate resistance to M. tuberculosis infections. It activates natural killer cells which produce IFN-γ to activate macrophages. By impairing the function of these two molecules by SHP-1 activation, ManLAM may promote intracellular survival.[2]

Other models suggest that ManLAM acts to mediate immunosuppressive effects through suppression of LPS-induced IL-12 p40 protein production. ManLAM is thought to inhibit the IL-1 receptor-associated kinase (IRAK)-TRAF6 interaction, IκB-α phosphorylation, and nuclear translocation of c-Rel and p50 which causes reduced IL-12 p40 production.[10]

PILAM

LAMS capped with phosphoinositol are typically found in nonpathogenic species including M. smegmatis. In contrast to ManLAMs, PILAMs are pro-inflammatory. CD14, a recognition receptor present on macrophages, associate with toll-like receptor 2 (TLR2) is described to be a receptor for PILAM.[11] Binding of PILAM to the receptor elicits the activation of an intracellular signaling cascade which activates transcription factors that initiate transcription of proinflammatory cytokine genes. This may lead to TNF-α, IL-8, and IL-12 activation and apoptosis of macrophages.[1][12]

AraLAM (CheLAM)

Certain species of rapid-growing bacterium such as M. chelonae and laboratory strains (H37Ra) contain LAMs that are absent of both mannose and phosphoinosital caps.[1] This form of LAM is characterized by 1,3 –mannosyl side chains instead of the 1,2 commonly found in others mycobacterial species.[12] These forms are considered to be more potent than the mannose-capped ManLAM in inducing functions associated with macrophage activation.[9] In addition to stimulation of early genes such as c-fos, KC, and JE, AraLAM induces transcription of the mRNA for cytokines (such as TNF-α, IL 1-α, IL 1-β, IL-6, IL-8, and IL-10) characteristically produced by macrophages.[2][9] Proto-oncogenes c-fos and c-myc are involved in the regulation of gene transcription while JE and KC are peptide cytokines that serve as specific chemoattractants for neutrophils and monocytes.[13] Activation of TNF-α creates pathologic manifestations of disease such as tissue necrosis, nerve damage, and protective immunity. [14] O-acyl groups of the arabinomannan moiety may be responsible for TNF-inducing activity which causes the tuberculosis symptoms of fever, weight loss, and necrosis.[15] However, the presence of ManLAMs decreases AraLAM activity, suppressing an immune response.[9]

References

  1. 1 2 3 4 Guérardel, Yann; et al. (2003). "Lipomannan and Lipoarabinomannan from a Clinical Isolate of Mycobacterium kansasii". Journal of Biological Chemistry 278 (38): 36637–36651. doi:10.1074/jbc.M305427200. PMID 12829695.
  2. 1 2 3 4 Knutson, Keith; et al. (1998). "Lipoarabinomannan of Mycobacterium tuberculosisPromotes Protein Tyrosine Dephosphorylation and Inhibition of Mitogen-activated Protein Kinase in Human Mononuclear Phagocytes". Journal of Biological Chemistry 273 (1): 645–652. doi:10.1074/jbc.273.1.645. PMID 9417127.
  3. ↑ Chan, J; et al. (1991). "Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages". Infectious Immunology 59 (5): 1755–1761. PMC 257912. PMID 1850379.
  4. ↑ Kordulakova, Jana; et al. (2002). "Definition of the First Mannosylation Step in Phosphatidylinositol Mannoside Synthesis". Journal of Biological Chemistry 277 (35): 31335–31344. doi:10.1074/jbc.m204060200.
  5. ↑ Lea-Smith, David J.; et al. (2008). "Analysis of a New Mannosyltransferase Required for the Synthesis of Phosphatidylinositol Mannosides and Lipoarbinomannan Reveals Two Lipomannan Pools in Corynebacterineae". Journal of Biological Chemistry 283 (11): 6773–6782. doi:10.1074/jbc.m707139200.
  6. ↑ Morita, Yasu S.; et al. (2006). "PimE is a polyprenol-phosphate-mannose-dependent mannosyltransferase that transfers the fifth mannose of phosphatidylinositol mannoside in mycobacteria". Journal of Biological Chemistry 281 (35): 25143–25155. doi:10.1074/jbc.m604214200.
  7. 1 2 Guérardel, Yann; et al. (2003). "Structural Study of Lipomannan and Lipoarabinomannan fromMycobacterium chelonae". Journal of Biological Chemistry 277 (34): 30635–30648. doi:10.1074/jbc.M204398200. PMID 12063260.
  8. 1 2 Maiti, Debasish; et al. (2001). ". Lipoarabinomannan from Mycobacterium tuberculosis Promotes Macrophage Survival by Phosphorylating Bad through a Phosphatidylinositol 3-Kinase/Akt Pathway". Journal of Biological Chemistry 276 (1): 329–333. doi:10.1074/jbc.M002650200. PMID 11020382.
  9. 1 2 3 4 Gilleron, Martine; et al. (1997). "Mycobacterium smegmatis Phosphoinositols-Glyceroarabinomannans". PNAS – Microbiology 271 (1): 117–124. PMID 8995236.
  10. ↑ Pathak, Sushil Kumar; et al. (2005). "Mycobacterium tuberculosis Lipoarabinomannan-mediated IRAK-M Induction Negatively Regulates Toll-like Receptor-dependent Interleukin-12 p40 Production in Macrophages". Journal of Biological Chemistry 280 (52): 42794–42800. doi:10.1074/jbc.M506471200. PMID 16263713.
  11. ↑ Yu, Weiming; et al. (1998). "Soluble CD141-152 Confers Responsiveness to Both Lipoarabinomannan and Lipopolysaccharide in a Novel HL-60 Cell Bioassay". Journal of Immunology 161 (8): 4244–4251. PMID 9780199.
  12. 1 2 Vignal, Cecile; et al. (2003). "Lipomannans, But Not Lipoarabinomannans, Purified from Mycobacterium chelonae and Mycobacterium kansasii Induce TNF-{alpha} and IL-8 Secretion by a CD14-Toll-Like Receptor 2-Dependent Mechanism". Journal of Immunology 171 (4): 10989–10994. PMID 12902506.
  13. ↑ Roach, TI; et al. (1993). "Macrophage activation: lipoarabinomannan from avirulent and virulent strains of Mycobacterium tuberculosis differentially induces the early genes c-fos, KC, JE, and tumor necrosis factor-alpha". Journal of Immunology 150 (5): 1886–1896. PMID 8436823.
  14. ↑ Barnes, PF; et al. (1992). "Tumor necrosis factor production in patients with leprosy". Infectious Immunology 60 (4): 1441–1446. PMC 257016. PMID 1548069.
  15. ↑ Moreno, C; et al. (1989). "Lipoarabinomannan from Mycobacterium tuberculosis induces the production of tumour necrosis factor from human and murine macrophages". Clin Exp Immunol. 76 (2): 240–245. PMC 1541837. PMID 2503277.

Further reading

This article is issued from Wikipedia - version of the Monday, September 14, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.